Retrospect and reflection: the past 30 years of research on hepatitis C prophylaxis and treatment
10.3969/j.issn.1001-5256.2015.11.009
- VernacularTitle:回顾与思考——丙型肝炎防治研究三十年
- Author:
Zhansheng JIA
1
Author Information
1. Centre of Diagnosis and Treatment for Infectious Diseases of Chinese PLA, Tangdu Hospital, Fourth Military Medical University, Xi′an 710038, China
- Publication Type:Research Article
- Keywords:
hepatitis C;
antiviral agents;
viral hepatitis vaccines
- From:
Journal of Clinical Hepatology
2015;31(11):1803-1806
- CountryChina
- Language:Chinese
-
Abstract:
The research on prophylaxis and treatment of hepatitis C has been performed for more than 30 years, with outstanding achievements. The discovery and confirmation of hepatitis C virus (HCV) was a milestone for how humans discovered new life. Emphasis on HCV molecular biology, infection immunity, and pathogenesis is the basic rule for scientific research on infectious diseases. PEG-IFN combined with ribavirin as the standardized antiviral treatment has been a great success; this combination therapy achieves a sustained viral response more than 80% in Chinese people, which is a typical example for successful clinical application of cytokines. Direct-acting antiviral agent(DAA) or combined application has made it possible to cure all patients infected with hepatitis C, which is the most successful example for reference. Persistent viral infection and maintenance of immune homeostasis under certain conditions are the results of the interaction between the host and the virus, and the development of vaccines will be continued.
